Sakshi Sardar, United States of America

Critical Path Institute Quantitative Medicine
Sakshi Sardar received the B.Tech. degree in electronics and communication engineering from the National Institute of Technology, Durgapur, India, in 2012, and the M.S. degree in biomedical engineering and the Ph.D. degree in electrical and computer engineering, and quantitative biomedicine from Rutgers University, in 2016 and 2019, respectively. She has research experience in nanoparticle synthesis and, micro and nano-engineered systems development for analyte detection. She has also worked with data processing and machine learning for different sensing modalities. She is currently a Quantitative Medicine Scientist with the Critical Path Institute (C-Path), working on digital health technologies for drug development tools. At C-Path, her efforts are focused on quantitatively linking the measurements from mobile sensing technologies to clinically meaningful aspects in Parkinson’s disease and type-1 diabetes. Her research interests include sensor design using nanomaterials, sensor data analytics, and data-driven approaches for decision making.

Presenter of 2 Presentations

ADVANCING DIGITAL TECHNOLOGIES FOR PARKINSON’S: A PATIENT-CENTRIC STRATEGY

Session Type
SYMPOSIUM
Date
14.03.2021, Sunday
Session Time
12:00 - 13:45
Room
On Demand Symposia B
Lecture Time
12:15 - 12:30
Session Icon
On-Demand

Abstract

Aims

To develop a patient-centric strategy to advance the use of digital health technologies in Parkinson’s disease (PD) clinical trials.

Methods

Three source-domains were defined to generate comprehensive inventories to inform the regulatory strategy for PD: Voice of the Patient (VoP), existing clinical outcome assessments (COAs), and studies employing digital health technologies (DHTs). For VoP, 38 publications were selected for assessment from 69 publications after initial screening. For COAs, 172 COAs from 22 publications identified by the Movement Disorder Society (MDS) task force were screened. For studies employing DHTs, 67 distinct studies were identified.

Results

VoP assessment provided information about clinical manifestations and their importance. Quantitative metrics were used to rank the symptoms important to patients. For the identified symptoms, existing COAs were assessed for limitations in addressing signs and symptoms of PD, and for the possibility of utilizing DHTs to improve clinical assessments. Integration of information from the three source-domains resulted in creating a process flow to assess the maturity of DHTs to monitor clinically meaningful features of PD, and for engaging regulatory agencies. This methodology results in identification of gait, sleep, speech, etc. as more mature concepts in comparison to muscle ache, digestive issues, comprehension etc. on the targeted maturity continuum.

Conclusions

The proposed patient-centric strategy provides a methodology to assess gaps that exist in quantifying PD symptom burden and identify areas to facilitate advancement of DHTs in PD clinical trials. This process assists in identifying symptoms to target for future DHT development and regulatory use in PD drug development.

Hide